Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta‐Analysis

Therapeutic response to metformin, a first‐line drug for type 2 diabetes (T2D), is highly variable, in part likely due to genetic factors. To date, metformin pharmacogenetic studies have mainly focused on the impact of variants in metformin transporter genes, with inconsistent results. To clarify the significance of these variants in glycemic response to metformin in T2D, we performed a large‐scale meta‐analysis across the cohorts of the Metformin Genetics Consortium (MetGen). Nine candidate polymorphisms in five transporter genes (organic cation transporter [OCT]1, OCT2, multidrug and toxin extrusion transporter [MATE]1, MATE2‐K, and OCTN1) were analyzed in up to 7,968 individuals. None of the variants showed a significant effect on metformin response in the primary analysis, or in the exploratory secondary analyses, when patients were stratified according to possible confounding genotypes or prescribed a daily dose of metformin. Our results suggest that candidate transporter gene variants have little contribution to variability in glycemic response to metformin in T2D.

• Publication year

  2017

• Venue

  Clinical pharmacology and therapy

• Publication date

  2017-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cpt.567PMID 27859023PMCID 5425333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin and the gastrointestinal tract

  2016cited by this paper
• Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food

  2016cited by this paper
• The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

  2016cited by this paper
• The Human Gut Microbiota.

  2016cited by this paper
• Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin

  2016cited by this paper
• Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin

  2015cited by this paper
• Four Cation-Selective Transporters Contribute to Apical Uptake and Accumulation of Metformin in Caco-2 Cell Monolayers

  2015cited by this paper
• Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study

  2015cited by this paper
• The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

  2015cited by this paper
• Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes

  2015cited by this paper
• Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats

  2015cited by this paper
• Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial

  2015cited by this paper
• Characterizing Race/Ethnicity and Genetic Ancestry for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort

  2015cited by this paper
• Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota

  2015cited by this paper
• Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).

  2015cited by this paper
• A Comprehensive Review of Drug–Drug Interactions with Metformin

  2015cited by this paper
• Genotyping Informatics and Quality Control for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort

  2015cited by this paper
• Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

  2014cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin

  2014cited by this paper
• Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis

  2014cited by this paper
• An update on the pharmacogenomics of metformin: progress, problems and potential.

  2014cited by this paper
• Metformin: from mechanisms of action to therapies.

  2014cited by this paper
• Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study

  2014cited by this paper
• Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus

  2014cited by this paper
• Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

  2014cited by this paper
• Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research

  2014cited by this paper
• Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

  2013cited by this paper
• The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

  2013cited by this paper
• Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

  2013cited by this paper
• Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes

  2013cited by this paper
• Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach

  2013cited by this paper
• Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

  2013cited by this paper
• Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects

  2013cited by this paper
• Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

  2013cited by this paper
• Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin.

  2013cited by this paper
• International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms

  2013cited by this paper
• A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin

  2013cited by this paper
• Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen‐induced arthritic rats

  2013cited by this paper
• Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

  2012cited by this paper
• A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.

  2012cited by this paper
• A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

  2012cited by this paper
• Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

  2012cited by this paper
• Dosing Frequency and Medication Adherence in Chronic Disease

  2012cited by this paper
• Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

  2012cited by this paper
• Meta‐analysis of gene‐environment interaction: joint estimation of SNP and SNP × environment regression coefficients

  2011cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2011cited by this paper
• Next generation genome-wide association tool: design and coverage of a high-throughput European-optimized SNP array.

  2011cited by this paper
• The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

  2011cited by this paper
• Population pharmacokinetic–pharmacodynamic–disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis

  2011cited by this paper
• Optimizing the technological and informational relationship of the health care process and of the communication between physician and patient. The impact of Preventive Medicine and social marketing applied in Health Care on youth awareness–Preliminary study

  2011cited by this paper
• A Common 5′‐UTR Variant in MATE2‐K Is Associated With Poor Response to Metformin

  2011cited by this paper
• Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects

  2011cited by this paper
• Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

  2011cited by this paper
• A case study of model‐based Bayesian dose response estimation

  2011cited by this paper
• Pharmacokinetic-Pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis

  2011cited by this paper
• Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program

  2010cited by this paper
• Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

  2010cited by this paper
• Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

  2010cited by this paper
• Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

  2010cited by this paper
• Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron

  2010cited by this paper
• Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response

  2010cited by this paper
• Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

  2009cited by this paper
• Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study

  2009cited by this paper
• Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

  2009cited by this paper
• Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.

  2009cited by this paper
• The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

  2009cited by this paper
• The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

  2009cited by this paper
• Effect of medication dosing frequency on adherence in chronic diseases.

  2009cited by this paper
• Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study

  2009cited by this paper
• Pharmacokinetics of dexamethasone in a rat model of rheumatoid arthritis

  2008cited by this paper
• Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis

  2008cited by this paper
• Quantitative Dynamic Models of Arthritis Progression in the Rat

  2008cited by this paper
• Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

  2008cited by this paper
• Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics

  2008cited by this paper
• OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

  2008cited by this paper
• Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats

  2008cited by this paper
• PLINK: a tool set for whole-genome association and population-based linkage analyses.

  2007cited by this paper
• Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

  2007cited by this paper
• Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications

  2007cited by this paper
• Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine

  2007cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.

  2006cited by this paper
• Drug specificity and intestinal membrane localization of human organic cation transporters (OCT).

  2005cited by this paper
• A human transporter protein that mediates the final excretion step for toxic organic cations.

  2005cited by this paper
• Cytokine networks—towards new therapies for rheumatoid arthritis

  2005cited by this paper
• Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2

  2005cited by this paper
• Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations.

  2004cited by this paper
• Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin

  2002cited by this paper
• Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

  1998cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

  1995cited by this paper
• Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study

  1994cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper

• Intracellular Pharmacokinetics of Antidiabetic Drugs: A Focused Narrative Review of Subcellular Distribution (2015-2025).

  2026cites this paper
• Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktail

  2025cites this paper
• Drug Transporters Polymorphism Among Indonesian Population: A Review

  2025cites this paper
• Genetic Variants of SLC22A1 rs628031 and rs622342 and Glycemic Control in T2DM Patients from Northern Mexico

  2025cites this paper
• A critical role for Phocaeicola vulgatus in negatively impacting metformin response in diabetes

  2025cites this paper
• The effect of genetic variants of SLC22A2 (rs662301 and rs315978) on the response to metformin in type 2 Saudi diabetic patients.

  2024cites this paper
• Association of the Reduced Function Met420del Polymorphism of SLC22A1 with Metformin-Induced Gastrointestinal Intolerance in Ethiopian Patients with Type 2 Diabetes Mellitus

  2024cites this paper
• Understanding the action mechanisms of metformin in the gastrointestinal tract

  2024cites this paper
• Effects of Xhosa specific solute carrier family 22-member 2 haplotypes on the cellular uptake of metformin and cimetidine.

  2024cites this paper
• Exploring the impact of pharmacogenetics on personalized medicine: A systematic review.

  2024cites this paper
• Metformin-Induced Chronic Diarrhea Misdiagnosed as Irritable Bowel Syndrome for Years

  2024cites this paper
• Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes

  2024cites this paper
• Health disparities in the risk of severe acidosis: real-world evidence from the All of Us cohort

  2024cites this paper
• Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration

  2024cites this paper
• Exploring the impact of pharmacogenetics on personalized medicine: A systematic review.

  2024cites this paper
• Association of Met420del Variant of Metformin Transporter Gene SLC22A1 with Metformin Treatment Response in Ethiopian Patients with Type 2 Diabetes

  2023influential citation
• Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?

  2023cites this paper
• Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis

  2023cites this paper
• Genetic variation in organic cation transporters and considerations in drug development

  2023influential citation
• Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers

  2023influential citation
• A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes

  2023influential citation
• Impact of solute carrier transporter gene polymorphisms on serum creatinine concentrations in healthy volunteers

  2023cites this paper
• A Metformin Pharmacogenetic Study of Patients with Type 2 Diabetes Mellitus and SLC22A1 Gene Mutation

  2022cites this paper
• Clinical Study on the Relationship between the SNP rs8192675 (C/C) Site of SLC2A2 Gene and the Hypoglycemic Effect of Metformin in Type 2 Diabetes

  2022cites this paper
• Pharmacogenetic Variation and Its Clinical Relevance in a Latin American Rural Population

  2022cites this paper
• The determination of the effect(s) of solute carrier family 22-member 2 (SLC22A2) haplotype variants on drug binding via molecular dynamic simulation systems

  2022cites this paper
• Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.

  2022cites this paper
• Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus

  2022cites this paper
• Metformin: a promising antidiabetic medication for cancer treatment.

  2022cites this paper
• Precision Medicine in Diabetes.

  2022cites this paper
• Association of SLC47A1 gene variant with responses to metformin monotherapy in drug-naïve patients with type 2 diabetes: A systematic review and meta-analysis.

  2022cites this paper
• Allele Frequency of a Common Variants and Two Common Loss-of-Function Variants in Organic Cation Transporter 1 (OCT1) among Balinese Diabetic Patients

  2022cites this paper
• Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia

  2022cites this paper
• The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.

  2022cites this paper
• A Two-Stage Study Identifies Two Novel Polymorphisms in PRKAG2 Affecting Metformin Response in Chinese Type 2 Diabetes Patients

  2021cites this paper
• Codeine , morphine , and metformin : Common aspects of drug transport , drug-drug interactions , and pharmacogenetics

  2021cites this paper
• Données récentes sur le mécanisme d’action de la metformine dans le diabète de type 2

  2021cites this paper
• Pharmacogenomics Based Study for Liraglutide And Metfromin (PCOS Drugs) Efficacy In Populations Across The Globe

  2021cites this paper
• OCT1 Polyspecificity—Friend or Foe?

  2021cites this paper
• Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes

  2021cites this paper
• From Pharmacogenetics to Gene Expression: Implications for Precision Medicine in Diabetes

  2021cites this paper
• Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression

  2021cites this paper
• Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects

  2021cites this paper
• The Current and Potential Therapeutic Use of Metformin—The Good Old Drug

  2021cites this paper
• PGPM_A_305020 745..755

  2021cites this paper
• Differences in Metformin and Thiamine Uptake between Human and Mouse Organic Cation Transporter 1: Structural Determinants and Potential Consequences for Intrahepatic Concentrations

  2020cites this paper
• Organic Cation Transporters in Health and Disease

  2020influential citation
• Objectives, design and main findings until 2020 from the Rotterdam Study

  2020cites this paper
• Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2020cites this paper
• Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2020cites this paper
• Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes

  2020cites this paper
• Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.

  2020cites this paper
• Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients

  2020cites this paper
• Letter to the Editor: “Association between metformin medication, genetic variation and prostate cancer risk”—genotyping and patient categorizations, do they matter?

  2020cites this paper
• The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition

  2020cites this paper
• Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes

  2020cites this paper
• Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

  2020cites this paper
• A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas

  2020cites this paper
• Using a limited sampling strategy to investigate the interindividual pharmacokinetic variability in metformin: A large prospective trial

  2020cites this paper
• DMSO_A_235663 2069..2080

  2020cites this paper
• Letter to the Editor: “Association between metformin medication, genetic variation and prostate cancer risk”—genotyping and patient categorizations, do they matter?

  2020cites this paper
• Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake

  2019cites this paper
• Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine

  2019cites this paper
• Metabolic Effects of Metformin in Humans.

  2019cites this paper
• Pharmacology of metformin - An update.

  2019cites this paper
• A Study of the Effects of Metformin, a Biguanide Derivative, on Annulus Fibrosus and Nucleus Pulposus Cells.

  2019cites this paper
• Clinical and genetic predictors of diabetes drug’s response

  2019cites this paper
• Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

  2019cites this paper
• TCF 7 L 2 and metformin response Effects of TCF 7 L 2 rs 7903146 variant on metformin response in patients with type 2 diabetes

  2019cites this paper
• The influence of SLC22A1 rs622342 and ABCC8 rs757110 genetic variants on the efficacy of metformin and glimepiride combination therapy in Egyptian patients with type 2 diabetes

  2019cites this paper
• Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes.

  2019cites this paper
• Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study

  2019cites this paper
• Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels

  2019cites this paper
• The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial

  2018cites this paper
• Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

  2018cites this paper
• OCTN: A Small Transporter Subfamily with Great Relevance to Human Pathophysiology, Drug Discovery, and Diagnostics

  2018cites this paper
• Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients

  2018cites this paper
• Metformin transporter pharmacogenomics: insights into drug disposition—where are we now?

  2018cites this paper
• Using a semi‐mechanistic model to identify the main sources of variability of metformin pharmacokinetics

  2018cites this paper
• Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol

  2018cites this paper
• Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes

  2018cites this paper
• Pharmacogenetics of Antidiabetic Drugs.

  2018cites this paper
• A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT.

  2018cites this paper
• Presentations and Posters

  2018cites this paper
• Pharmacogenetics of oral antidiabetic therapy.

  2018cites this paper
• Pharmacogenetics and target identification in diabetes.

  2018cites this paper
• Biomarkers for In Vivo Assessment of Transporter Function

  2018cites this paper
• Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort

  2018cites this paper
• The Effects of Metformin on the Metabolism of Colorectal Cancer Cell Lines SW948 and SW1116

  2018cites this paper
• Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes

  2017cites this paper
• The importance of drug transporter characterization to precision medicine

  2017cites this paper
• Gestational diabetes mellitus—right person, right treatment, right time?

  2017cites this paper
• How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?

  2017cites this paper
• Transporters Involved in Metformin Pharmacokinetics and Treatment Response.

  2017cites this paper
• Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo

  2017cites this paper
• Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?

  2017cites this paper
• The pharmacogenetics of metformin

  2017influential citation
• The mechanisms of action of metformin

  2017cites this paper
• The Rotterdam Study: 2018 update on objectives, design and main results

  2017cites this paper
• Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans

  2017cites this paper